SAN BRUNO, Calif.--(BUSINESS WIRE)--Numerate, Inc., a biotechnology company leveraging a novel drug engineering process to design lead-stage drug compounds, announced today that it has completed a $4 million Series A financing. Investors included Foundation Capital, Lanza techVentures and various individuals. Concurrent with the financing, Adam Grosser, a general partner with Foundation Capital, has joined Numerate’s Board of Directors.
